WAW-TACE
model2026-01-24https://doi.org/10.1148/atlas.1763759637483
90

Overview

Schema Version

https://atlas.rsna.org/schemas/2025-11/model.json

Name

WAW-TACE

Link

https://zenodo.org/records/12741586

Indexing

Keywords: Liver, Oncology, Hepatocellular Carcinoma, HCC, TACE, Transarterial Chemoembolization, Multiphase CT, Radiomics, Segmentation, Clinical outcomes, Overall survival, Progression-free survival
Content: CT, GI, OI
RadLex: RID49459, RID12778, RID1647, RID4273, RID14317, RID13060

Author(s)

Krzysztof Bartnik
Tomasz Bartczak
Mateusz Krzyziński
Krzysztof Korzeniowski
Krzysztof Lamparski
Piotr Węgrzyn
Eric Lam
Mateusz Bartkowiak
Tadeusz Wróblewski
Katarzyna Mech
Magdalena Januszewicz
Przemysław Biecek

Organization(s)

Medical University of Warsaw
Warsaw University of Technology
Ottawa Hospital Research Institute

Version

1.0

Contact

lp.ude.muw@kintrab.fotzsyzrk

Funding

Supported by the Medical University of Warsaw and the Warsaw University of Technology under collaborative grant “Integra WUM-PW” (no. 1W12/INTEGRA.1.6/N/23) and carried out with the support of the Laboratory of Bioinformatics and Computational Genomics and the High Performance Computing Center of the Faculty of Mathematics and Information Science Warsaw University of Technology.

Ethical review

Approved by the Bioethics Committee at the Medical University of Warsaw (decision no. AKBE/41/2024).

Date

Updated: 2024-11-01
Published: 2024-10-23
Created: 2024-05-13

References

[1] Bartnik K, Bartczak T, Krzyziński M, et al.. "WAW-TACE: A Hepatocellular Carcinoma Multiphase CT Dataset with Segmentations, Radiomics Features, and Clinical Data". Radiology: Artificial Intelligence. 2024 Nov;6(6):e240296.. 2024-10-23. doi:10.1148/ryai.240296. PMID: 39441110. PMCID: PMC11605144.

Model

Availability

Dataset available at https://zenodo.org/records/12741586 (see also data sharing statement link https://zenodo.org/records/11063785).

Clinical benefit

Resource to enable development and validation of AI models for HCC detection, segmentation, prognostication (e.g., treatment response, survival) and related research.

Indications for use

Research use: patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization; multiphase pre-TACE abdominal CT with lesion and organ segmentations, radiomics features, and extensive clinical data.

Input

Baseline multiphase abdominal CT (precontrast, late arterial, portal venous, delayed); associated clinical variables; segmentation masks (HCC lesions and 104 anatomic structures per phase).

Instructions

Data intended for scientific research purposes only; refer to accompanying documentation (clinical_data, ct_scans, tumor_masks, organ_masks, radiomics_data, ct_hcc_metadata) for variable definitions and imaging parameters.

Limitations

Only baseline imaging provided; not all patients have all CT phases; imaging from different CT systems with varying section thickness; no CT preprocessing or resampling prior to radiomics extraction; response assessments and PFS were based on reevaluation by one author following LI-RADS treatment response algorithm.

Output

CDEs: RDE65
Description: Dataset components include de-identified multiphase CT scans (NIfTI), HCC lesion masks (manual with corrections) and 104 organ VOIs per phase (automated via TotalSegmentator), tabular clinical data with outcomes (OS, PFS, treatment response), and extracted radiomics features per VOI.

Use

Intended: Methodological benchmarking, Interinstitutional comparisons, Cross-validation, Detection and diagnosis, Outcome prediction, Image segmentation

User

Intended: Physician, Radiologist, Researcher